Title : Pharmacoeconomic considerations for acute myeloid leukemia pharmacotherapy.

Pub. Date : 2022 Feb

PMID : 34886738






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Add-on drugs, namely midostaurin and gemtuzumab ozogamycin, have been reported to have the best pharmacoeconomic profile for newly diagnosed fit patients with FLT3 mutation or favorable/intermediate cytogenetics, since allogeneic transplant rates were stable or reduced. midostaurin fms related receptor tyrosine kinase 3 Homo sapiens